ABL1 and acute lymphoblastic leukemia: Finally, also the MA-SPORE ALL 2020 study (NCT06336395), ongoing in Malaysa and Singapore, and the NCT06257394 trial, ongoing in South Korea, include dasatinib for the treatment of Ph+ and ABL-class positive ALL pediatric patients.